Oncology
Targeted NGS Oncology Panel
Actionable genes, without the wait.
Targeted sequencing of driver genes for solid and hematologic tumors, with clinical interpretation and therapeutic options.
7–10 business days
Overview
The oncology panel covers genes frequently involved in solid and hematologic tumors. It identifies driver mutations, fusions and resistance variants useful for treatment decisions.
Analyses use FFPE tumor tissue or liquid biopsy, with sensitivity adapted to low-tumor-content samples.
Method & technologies
- 52-gene DNA/RNA panel
- Deep sequencing (≥ 500×)
- SNV, indel and fusion detection
- OncoKB annotation
Deliverables
- Prioritized clinical report
- Actionable variants with evidence level
- VCF
- Therapeutic recommendations